Bellido, F., Pineda, M., Aiza, G., Valdés-Mas, R., Navarro, M., Puente, D.A., Pons, T., González, S., Iglesias, S., Darder, E., et al. (2016). POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet. Med. 18, 325–332.
Benatti, P., Roncucci, L., Ganazzi, D., Percesepe, A., Di Gregorio, C., Pedroni, M., Borghi, F., Sala, E., Scarselli, A., Menigatti, M., et al. (2001). Clinical and biologic heterogeneity of hereditary nonpolyposis colorectal cancer. Int. J. Cancer 95, 323–328.
Choi, Y.-H., Lakhal-Chaieb, L., Kröl, A., Yu, B., Buchanan, D., Ahnen, D., Le Marchand, L., Newcomb, P.A., Win, A.K., Jenkins, M., et al. (2019). Risks of Colorectal Cancer and Cancer-Related Mortality in Familial Colorectal Cancer Type X and Lynch Syndrome Families. J. Natl. Cancer Inst. 111, 675–683.
Chun, N., and Ford, J.M. (2012). Genetic Testing by Cancer Site: Stomach. Cancer J. 18, 355–363.
Dominguez-Valentin, M., Nakken, S., Tubeuf, H., Vodak, D., Ekstrøm, P.O., Nissen, A.M., Morak, M., Holinski-Feder, E., Martins, A., Møller, P., et al. (2018). Identification of genetic variants for clinical management of familial colorectal tumors. BMC Med. Genet. 19.
Dove-Edwin, I., de Jong, A.E., Adams, J., Mesher, D., Lipton, L., Sasieni, P., Vasen, H.F.A., and Thomas, H.J.W. (2006). Prospective results of surveillance colonoscopy in dominant familial colorectal cancer with and without Lynch syndrome. Gastroenterology 130, 1995–2000.
Engel, C., Loeffler, M., Steinke, V., Rahner, N., Holinski-Feder, E., Dietmaier, W., Schackert, H.K., Goergens, H., von Knebel Doeberitz, M., Goecke, T.O., et al. (2012). Risks of less common cancers in proven mutation carriers with lynch syndrome. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 30, 4409–4415.
Engel, G., Ferlay, J., Christensen, N., Kejs, A.M.T., Johannesen, T.B., Khan, S., Milter, M.C., Ólafsdóttir, E., Petersen, T., Pukkala, E., et al. (2016). NORDCAN: Cancer Incidence, Mortality, Prevalence and Survival in the Nordic Countries, Version 7.0 (17.12.2014). Available at: http:// www.ancr.nu Association of the Nordic Cancer Registries. Danish Cancer Society (accessed on 14 April 2016).
Garre, P., Briceño, V., Xicola, R.M., Doyle, B.J., Hoya, M. de la, Sanz, J., Llovet, P., Pescador, P., Puente, J., Díaz-Rubio, E., et al. (2011). Analysis of the Oxidative Damage Repair Genes NUDT1, OGG1, and MUTYH in Patients from Mismatch Repair Proficient HNPCC Families (MSS-HNPCC). Clin. Cancer Res. 17, 1701–1712.
Garre, P., Martín, L., Sanz, J., Romero, A., Tosar, A., Bando, I., Llovet, P., Diaque, P., García-Paredes, B., Díaz-Rubio, E., et al. (2015). BRCA2 gene: a candidate for clinical testing in familial colorectal cancer type X. Clin. Genet. 87, 582–587.
Gu, J., and Wu, X. (2011). Genetic susceptibility to bladder cancer risk and outcome. Pers. Med. 8, 365–374.
Hansen, M.F., Johansen, J., Bjørnevoll, I., Sylvander, A.E., Steinsbekk, K.S., Sætrom, P., Sandvik, A.K., Drabløs, F., and Sjursen, W. (2015). A novel POLE mutation associated with cancers of colon, pancreas, ovaries and small intestine. Fam. Cancer 14, 437–448.
Harbour, J.W., Onken, M.D., Roberson, E.D.O., Duan, S., Cao, L., Worley, L.A., Council, M.L., Matatall, K.A., Helms, C., and Bowcock, A.M. (2010). Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas. Science 330, 1410–1413.
Hatfield, E., Green, J.S., Woods, M.O., Warden, G., and Parfrey, P.S. (2018). Impact of colonoscopic screening in Familial Colorectal Cancer Type X. Mol. Genet. Genomic Med. 6, 1021–1030.
Helgadottir, H., and Höiom, V. (2016). The genetics of uveal melanoma: current insights. Appl. Clin. Genet. Volume 9, 147–155.
Ishaq, S., and Nunn, L. (2015). Helicobacter pylori and gastric cancer: a state of the art review. Gastroenterol. Hepatol. Bed Bench 8, S6–S14.
Joost, P., Therkildsen, C., Dominguez-Valentin, M., Jönsson, M., and Nilbert, M. (2015). Urinary Tract Cancer in Lynch Syndrome; Increased Risk in Carriers of MSH2 Mutations. Urology 86, 1212–1217.
Kastrinos, F., Mukherjee, B., Tayob, N., Wang, F., Sparr, J., Raymond, V.M., Bandipalliam, P., Stoffel, E.M., Gruber, S.B., and Syngal, S. (2009). Risk of pancreatic cancer in families with Lynch syndrome. JAMA 302, 1790–1795.
Klarskov, L., Holck, S., Bernstein, I., and Nilbert, M. (2012). Hereditary colorectal cancer diagnostics: morphological features of familial colorectal cancer type X versus Lynch syndrome. J. Clin. Pathol. 65, 352–356.
Lindberg, L.J., Ladelund, S., Frederiksen, B.L., Smith-Hansen, L., and Bernstein, I. (2017). Outcome of 24 years national surveillance in different hereditary colorectal cancer subgroups leading to more individualised surveillance. J. Med. Genet. 54, 297–304.
Lindor, N.M., Rabe, K., Petersen, G.M., Haile, R., Casey, G., Baron, J., Gallinger, S., Bapat, B., Aronson, M., Hopper, J., et al. (2005). Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA 293, 1979–1985.
Mueller-Koch, Y., Vogelsang, H., Kopp, R., Lohse, P., Keller, G., Aust, D., Muders, M., Gross, M., Daum, J., Schiemann, U., et al. (2005). Hereditary non-polyposis colorectal cancer: clinical and molecular evidence for a new entity of hereditary colorectal cancer. Gut 54, 1733–1740.
Nejadtaghi, M., Jafari, H., Farrokhi, E., and Samani, K.G. (2017). Familial Colorectal Cancer Type X (FCCTX) and the correlation with various genes-A systematic review. Curr. Probl. Cancer 41, 388–397.
Nieminen, T.T., Abdel–Rahman, W.M., Ristimäki, A., Lappalainen, M., Lahermo, P., Mecklin, J., Järvinen, H.J., and Peltomäki, P. (2011). BMPR1A Mutations in Hereditary Nonpolyposis Colorectal Cancer Without Mismatch Repair Deficiency. Gastroenterology 141, e23–e26.
Nieminen, T.T., O’Donohue, M.-F., Wu, Y., Lohi, H., Scherer, S.W., Paterson, A.D., Ellonen, P., Abdel-Rahman, W.M., Valo, S., Mecklin, J.-P., et al. (2014). Germline Mutation of RPS20, Encoding a Ribosomal Protein, Causes Predisposition to Hereditary Nonpolyposis Colorectal Carcinoma Without DNA Mismatch Repair Deficiency. Gastroenterology 147, 595-598.e5.
van der Post, R.S., Vogelaar, I.P., Carneiro, F., Guilford, P., Huntsman, D., Hoogerbrugge, N., Caldas, C., Chelcun Schreiber, K.E., Hardwick, R.H., Ausems, M.G.E.M., et al. (2015). Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J. Med. Genet. 52, 361–374.
van der Post, R.S., Oliveira, C., Guilford, P., and Carneiro, F. (2019). Hereditary gastric cancer: what’s new? Update 2013-2018. Fam. Cancer 18, 363–367.
Rostgaard, K. (2008). Methods for stratification of person-time and events - a prerequisite for Poisson regression and SIR estimation. Epidemiol. Perspect. Innov. 5.
Schulz, E., Klampfl, P., Holzapfel, S., Janecke, A.R., Ulz, P., Renner, W., Kashofer, K., Nojima, S., Leitner, A., Zebisch, A., et al. (2014). Germline variants in the SEMA4A gene predispose to familial colorectal cancer type X. Nat. Commun. 5, 1–11.
Shiovitz, S., Copeland, W.K., Passarelli, M.N., Burnett-Hartman, A.N., Grady, W.M., Potter, J.D., Gallinger, S., Buchanan, D.D., Rosty, C., Win, A.K., et al. (2014). Characterisation of familial colorectal cancer Type X, Lynch syndrome, and non-familial colorectal cancer. Br. J. Cancer 111, 598–602.
Storm, H.H. (1988). Completeness of cancer registration in Denmark 1943-1966 and efficacy of record linkage procedures. Int. J. Epidemiol. 17, 44–49.
Storm, H.H., Michelsen, E.V., Clemmensen, I.H., and Pihl, J. (1997). The Danish Cancer Registry--history, content, quality and use. Dan. Med. Bull. 44, 535–539.
Therkildsen, C., Ladelund, S., Smith-Hansen, L., Lindberg, L.J., and Nilbert, M. (2017). Towards gene- and gender-based risk estimates in Lynch syndrome; age-specific incidences for 13 extra-colorectal cancer types. Br. J. Cancer 117, 1702–1710.
Valle, L. (2014). Genetic predisposition to colorectal cancer: where we stand and future perspectives. World J. Gastroenterol. 20, 9828–9849.
Valle, L. (2017). Recent Discoveries in the Genetics of Familial Colorectal Cancer and Polyposis. Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc. 15, 809–819.
Valle, L., Perea, J., Carbonell, P., Fernandez, V., Dotor, A.M., Benitez, J., and Urioste, M. (2007). Clinicopathologic and pedigree differences in amsterdam I-positive hereditary nonpolyposis colorectal cancer families according to tumor microsatellite instability status. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 25, 781–786.
Vasen, H.F., Mecklin, J.P., Khan, P.M., and Lynch, H.T. (1991). The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis. Colon Rectum 34, 424–425.
Vasen, H.F.A., Blanco, I., Aktan-Collan, K., Gopie, J.P., Alonso, A., Aretz, S., Bernstein, I., Bertario, L., Burn, J., Capella, G., et al. (2013). Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut 62, 812–823.
Win, A.K., Lindor, N.M., Young, J.P., Macrae, F.A., Young, G.P., Williamson, E., Parry, S., Goldblatt, J., Lipton, L., Winship, I., et al. (2012). Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome. J. Natl. Cancer Inst. 104, 1363–1372.
Xicola, R.M., Bontu, S., Doyle, B.J., Rawson, J., Garre, P., Lee, E., de la Hoya, M., Bessa, X., Clofent, J., Bujanda, L., et al. (2016). Association of a let-7 miRNA binding region of TGFBR1 with hereditary mismatch repair proficient colorectal cancer (MSS HNPCC). Carcinogenesis 37, 751–758.
Zeichner, S.B., Stanislaw, C., and Meisel, J.L. (2016). Prevention and Screening in Hereditary Breast and Ovarian Cancer. Oncol. Williston Park 30, 896–904.
Zetner, D.B., and Bisgaard, M.L. (2017). Familial Colorectal Cancer Type X. Curr. Genomics 18, 341–359.
Zhang, X., and Zhang, Y. (2015). Bladder Cancer and Genetic Mutations. Cell Biochem. Biophys. 73, 65–69.